Get the Stockscreener App
3.87
35.66%
1.00
Metavia Inc stock is traded at $3.87, with a volume of 39.18M.
It is up +35.66% in the last 24 hours and up +141.83% over the past month.
MetaVia Inc is a clinical-stage biotechnology company focused on developing novel pharmaceuticals to treat cardiometabolic diseases. It has two programs focused on the treatment of metabolic dysfunction-associated steatohepatitis (MASH) and obesity. Vanoglipel (DA-1241) is a novel GPR119 (GPR119) agonist with development optionality as a standalone or combination therapy for both MASH and Type 2 Diabetes Mellitus (T2DM). Agonism of GPR119 in the gut promotes the release of key gut peptides, glucagon-like peptide-1 (GLP-1), glucagon-dependent insulinotropic polypeptide receptor (GIP), and peptide YY.
See More
Previous Close:
$2.87
Open:
$3.56
24h Volume:
39.18M
Relative Volume:
13.08
Market Cap:
$19.93M
Revenue:
-
Net Income/Loss:
$-12.97M
P/E Ratio:
-0.6923
EPS:
-5.5898
Net Cash Flow:
$-15.70M
1W Performance:
+250.76%
1M Performance:
+141.83%
6M Performance:
-49.04%
1Y Performance:
-56.30%
1-Day Range:
$3.37
$4.31
1-Week Range:
$1.0804
$4.31
52-Week Range:
$0.9661
$19.03
Metavia Inc Stock (MTVA) Company Profile
Name
Metavia Inc
Sector
Industry
Phone
(857) 702-9600
Address
545 CONCORD AVENUE, CAMBRIDGE
Compare MTVA vs VRTX, REGN, ARGX, ALNY, RVMD
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
MTVA
Metavia Inc
|
3.86 | 14.82M | 0 | -12.97M | -15.70M | -5.5898 |
VRTX
Vertex Pharmaceuticals Inc
|
434.47 | 110.03B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
637.20 | 67.37B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
804.50 | 50.76B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
296.50 | 40.12B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
151.90 | 32.68B | 742.00K | -1.37B | -1.07B | -7.0731 |
Metavia Inc Stock (MTVA) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Sep-04-25 | Resumed | H.C. Wainwright | Buy |
| Dec-30-24 | Initiated | H.C. Wainwright | Buy |
Metavia Inc Stock (MTVA) Latest News
Why MetaVia Stock Is Surging On Friday? - Benzinga
MTVA Stock Explodes As ADA Conference Catalyst Ignites Momentum - StocksToTrade
MetaVia MTVA Stock Soars On ADA 2026 Cardio Breakthrough Buzz - timothysykes.com
$MetaVia (MTVA.US)$ ok im out now after hold for few days. - Moomoo
Maxim Group Maintains MetaVia(MTVA.US) With Buy Rating, Maintains Target Price $8 - Moomoo
Why MetaVia Stock Is Falling On Thursday? - Benzinga
Keep an eye on the top gainers and losers in Wednesday's session. - ChartMill
MetaVia announces preclinical study on vanoglipel published - Investing.com UK
MetaVia announces preclinical study on vanoglipel published By Investing.com - Investing.com Australia
MetaVia Highlights Peer-Reviewed Publication Supporting the Anti-Fibrotic Potential of Vanoglipel in MASH - PR Newswire
What's going on in today's session - ChartMill
Let's take a look at the stocks that are in motion in today's session. - ChartMill
MetaVia (MTVA) jumps 45.9% as traders react to ADA 2026 late-breaking poster news - Quiver Quantitative
MTVA Stock Sees Volatile Spike As Traders Eye Cash-Heavy Balance Sheet - StocksToTrade
MTVA Stock Sees Heavy Volatility As Traders Target Key Levels - timothysykes.com
Wondering what's happening in today's pre-market session? - ChartMill
12 Health Care Stocks Moving In Tuesday's Pre-Market Session - Benzinga
MetaVia Stock Moves Ahead of the Open After Obesity-Drug Data Picked for ADA - TechStock²
$MetaVia (MTVA.US)$ benefited from pre-m lets focus then for market hour 🫡 - Moomoo
MTVA Reiterated by HC Wainwright & Co. -- Price Target Maintained at $20 - GuruFocus
MetaVia Price Target Maintained With a $20.00/Share by HC Wainwright & Co. - Moomoo
Fein Reiterates Buy on MetaVia, Keeps DA-1726-Driven Price Target Unchanged at $20 - TipRanks
MetaVia to Present Promising Obesity and Diabetes Drug Data on DA-1726 and Vanoglipel at ADA 2026 Scientific Sessions - Minichart
MetaVia Showcases Key Cardiometabolic Data at ADA 2026 - TipRanks
MetaVia highlights promising obesity and metabolic disease drugs at ADA 2026 conference. - Pluang
MetaVia to Present Three Late-Breaking Posters on DA-1726 and Vanoglipel at ADA 2026 - TradingView
MetaVia (MTVA) highlights DA-1726 and vanoglipel data in ADA 2026 posters - Stock Titan
MetaVia to Present Obesity Data at the American Diabetes Association's (ADA) 2026 Scientific Sessions - ChartMill
Cotton Pushes Losses into the Friday Close - Barchart.com
Alyeska (MTVA) holds 508,585 exercisable shares; 9.99% cap limits exercises - Stock Titan
Why Super Micro (SMCI) Shares Are Plunging Today - Barchart.com
Wheat Extends Losses at Midday - Barchart.com
Bunker Hill Mining Corp. (BNKR) ouvre les marchés - Barchart.com
MTVA Technical Analysis | Trend, Signals & Chart Patterns | METAVIA INC (NASDAQ:MTVA) - ChartMill
1 Software Stock on Our Buy List and 2 We Avoid - Barchart.com
MetaVia Highlights Strong DA-1726 Phase 1 Weight-Loss Data - TipRanks
MTVA: Strong clinical pipeline in obesity and MASH targets high-growth markets with near-term catalysts - TradingView
MetaVia Inc reports results for the quarter ended March 31Earnings Summary - TradingView
MetaVia Inc. Reports Earnings Results for the First Quarter Ended March 31, 2026 - marketscreener.com
MetaVia (NASDAQ: MTVA) Q1 2026 loss, cash raise and going concern warning - Stock Titan
MetaVia (NASDAQ: MTVA) details Q1 2026 loss and DA-1726 obesity trial progress - Stock Titan
MetaVia Reports First Quarter 2026 Financial Results and Provides Corporate Update - PR Newswire
Meta Stock vs. Google Stock: One Is Clearly the Better Buy for the Next 10 Years - Barchart.com
Soybeans Technicals: Confirming the Double Top - Barchart.com
Cotton Collapsing Early on Thursday - Barchart.com
Soybeans Falling Back Following Trump/Xi meeting - Barchart.com
Obesity trial drug DA-1726 delivers 9.1% weight loss in 8 weeks - Stock Titan
OppFi Q1 Earnings Call Highlights - Barchart.com
The 5 Most Interesting Analyst Questions From Cloudflare’s Q1 Earnings Call - Barchart.com
Cotton Close with Modest Wednesday Gains - Barchart.com
MetaVia Moves DA-1726 Into Higher-Dose Territory as Phase 1 Data Build a Compelling Obesity Case - Barchart.com
Metavia Inc Stock (MTVA) Financials Data
Revenue
Net Income
Cash Flow
EPS
5.06%
1.20%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):